Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Fineline Cube Feb 27, 2026
Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Fineline Cube Feb 27, 2026
Policy / Regulatory

In-Depth Analysis of NHSA’s DRG/DIP Payment Reforms: A Path to Streamlined Healthcare Management

Fineline Cube Feb 10, 2025

Comprehensive Overhaul of Payment SystemsThe National Healthcare Security Administration (NHSA) has unveiled a series of...

Company Drug

CSPC Pharmaceutical’s mRNA Vaccine SYS6017 Gains NMPA Approval for Herpes Zoster Study

Fineline Cube Feb 8, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received approval from the...

Company Drug

Nuance Pharma’s Ohtuvayre Receives Regulatory Approval in Macau for COPD Treatment

Fineline Cube Feb 8, 2025

China-based Nuance Pharma announced that it has received regulatory approval in Macau for its Ohtuvayre...

Company

Regend Therapeutics’ Pulmovinci Receives FDA Orphan Drug Designation for IPF

Fineline Cube Feb 8, 2025

Suzhou-based stem cell therapy specialist Regend Therapeutics announced that the US Food and Drug Administration...

Company Drug

Sichuan Kelun-Biotech’s Datailai Gains NMPA Approval for Colorectal Cancer Treatment

Fineline Cube Feb 8, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received marketing approval...

Company Drug

CanSino Biologics’ DTcP Vaccine for Infants Gains Priority Review in China

Fineline Cube Feb 8, 2025

China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) announced that the New Drug Application (NDA)...

Company Drug

Keymed Biosciences’ Kangyueda Gains NMPA Approval for Seasonal Allergic Rhinitis

Fineline Cube Feb 8, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) announced that it has received another indication approval from...

Company Drug

Novo Nordisk’s Mim8 Shows Promise in Hemophilia A Trial with 98% Caregiver Preference

Fineline Cube Feb 8, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) released interim results from the Phase III FRONTIER3 study,...

Company

RemeGen’s Executive Director He Ruyi Resigns for Career Development

Fineline Cube Feb 8, 2025

China-based pharmaceutical firm RemeGen (HKG: 9995) announced the resignation of Mr. He Ruyi, Executive Director...

Company Drug

Biokin Pharmaceutical’s BL-M07D1 Gains NMPA Approval for Phase III Study

Fineline Cube Feb 8, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from...

Company Drug

AbbVie’s Emblaveo Wins FDA Approval for Complicated Intra-Abdominal Infections

Fineline Cube Feb 8, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval from the...

Company Drug

Zhongsheng Pharma Gains FDA Approval for Phase II Study of RAY1225

Fineline Cube Feb 8, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval from...

Company Medical Device

Siemens Healthineers Posts Strong Q1 Results with 5.7% Revenue Growth

Fineline Cube Feb 8, 2025

Germany-based Siemens Healthineers AG (ETR: SHL) released its results for the first quarter of fiscal...

Company Drug

Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA

Fineline Cube Feb 8, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306...

Company Deals

Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal

Fineline Cube Feb 8, 2025

Bain Capital is set to acquire Mitsubishi Tanabe Pharma Corporation (Tanabe Pharma) in a carve-out...

Company Deals

Henlius Biotech Licenses HLX15 to Dr. Reddy’s for US and European Markets

Fineline Cube Feb 7, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced a licensing deal with India-headquartered Dr. Reddy’s...

Company

Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches

Fineline Cube Feb 7, 2025

China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD...

Company

Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products

Fineline Cube Feb 7, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD...

Company Drug

CanSino’s Tetanus Vaccine NDA Accepted for Review by NMPA

Fineline Cube Feb 7, 2025

China-based vaccines specialist CanSino Biotechnology Inc. (HKG: 6185) announced that the National Medical Products Administration...

Company Drug

Huahai Pharma Set to Launch IL-17 Antibody HB0017 Clinical Study for HS

Fineline Cube Feb 7, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is poised to initiate a clinical study...

Posts pagination

1 … 178 179 180 … 627

Recent updates

  • Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars
  • Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion
  • Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry
  • Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate
  • Akeso’s Manfidokimab NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Company

Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion

Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.